Infectologia
EMA recomenda a aprovação da vacina da Pfizer-BioNTech para crianças de 5 a 11 anos.
26 Nov, 2021 | 12:06hConteúdos relacionados:
RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.
What COVID vaccines for young kids could mean for the pandemic.
CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.
FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.
Comentário no Twitter
‼️ EMA recommends approval of BioNTech/Pfizer’s #COVID19vaccine, Comirnaty, for children aged 5 to 11.
In this population, the dose of #Comirnaty will be lower than that used in people aged 12 and above.
Read the full press release: https://t.co/uqqBAklVvl pic.twitter.com/NZQhli4SDl
— EU Medicines Agency (@EMA_News) November 25, 2021
Revisão | Prevenção e tratamento de trombose em pacientes internados com pneumonia por COVID-19.
26 Nov, 2021 | 12:04hVariante fortemente mutada do coronavírus põe os cientistas em alerta – “Pesquisadores estão correndo para determinar se uma variante de alta transmissibilidade na África do Sul é uma ameaça à efetividade das vacinas contra COVID.”
26 Nov, 2021 | 12:03hHeavily mutated coronavirus variant puts scientists on alert – Nature
Ver também:
Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC
Scientists warn of new Covid variant with high number of mutations – The Guardian
South Africa detects new COVID variant with many mutations – MedicalXpress
Comentário relacionado no Twitter (fio – clique para saber mais)
THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today
TLDR: So much uncertain but what *is* known is extremely worrying & (in my opinion) we should revise red list immediately.
This is why: 1/16
— Prof. Christina Pagel (@chrischirp) November 25, 2021
Editorial | Vacine-se o mundo.
26 Nov, 2021 | 12:01h
Comentário do autor no Twitter
VAX THE WORLD!
is our wish/plea on #Thanksgiving day
Read our editorial in @ScienceMagazine by @yodifiji and me
Grateful to Lisa Chong, @hholdenthorp & @MeaganPhelan https://t.co/NiwMiEyCld pic.twitter.com/xbj0RF4lQe
— Madhu Pai, MD, PhD (@paimadhu) November 25, 2021
M-A | Comparação da eficácia clínica das vacinas contra COVID-19.
26 Nov, 2021 | 11:59hM-A | Sintomas persistentes após infecção por SARS-CoV-2 entre crianças e jovens – “Melhor qualidade de estudo foi associada com menor prevalência de todos os sintomas, exceto perda de olfato e sintomas cognitivos.”
26 Nov, 2021 | 11:58hConteúdos relacionados:
Review: Long COVID symptoms in children rarely persist beyond three months.
Cohort study: Risk factors for long covid in previously hospitalized children.
M-A: More than 50 long-term effects of COVID-19.
[Preprint] Respostas sorológicas ao reforço de vacina contra COVID-19 na Inglaterra.
26 Nov, 2021 | 11:56hSerological responses to COVID-19 booster vaccine in England – medRxiv
Comentário do autor no Twitter (fio – clique para saber mais)
1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵
— Shamez Ladhani (@ShamezLadhani) November 25, 2021
Diretriz provisória da OMS sobre a vacinação de crianças e adolescentes contra a COVID-19.
25 Nov, 2021 | 15:20hInterim statement on COVID-19 vaccination for children and adolescents – World Health Organization
Estudo de coorte baseado na população do Catar mostrou que as reinfecções tiveram 90% menos chances de resultar em internação ou morte do que as infecções primárias.
25 Nov, 2021 | 15:18hConteúdo relacionado: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
Reinfecção por COVID-19: o papel da imunidade natural, das vacinas e das variantes.
25 Nov, 2021 | 15:17hConteúdo relacionado: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.


